Valeant has also decided to sell Obagi. The company also sold iNova Pharmaceuticals for $930 million. Valeant’s stock has increased 1.5% in the last six months compared with the industry’s loss of 2.2%. The company is also divesting …
LAVAL, Quebec, Nov. 14, 2017 /PRNewswire/ -- Valeant Pharmaceuticals …
That means bottom fishers and deep-value investors are going to need patience to see Papa’s moves work their way into the stock price. Papa had a tough task …
Valeant Pharmaceuticals International (NYSE: VRX) stock is up by double-digits today on heavy volume as the result of a better-than-expected third-quarter earnings release. Although the company reported a $260 million dip in year-over-year …
Valeant Pharmaceuticals' (NYSE: VRX) is knee-deep in a transformation that it hopes will allow it to regain its top-tier status with investors. The company's selling assets and funneling cash flow into debt prepayments to rein in its interest …
But don't be too quick to call this a definitive turning point for Valeant's business or stock. There's still a lot of work to do, and previous efforts to call a bottom have been unsuccessful. This column does not necessarily reflect the opinion of ...
November 08 was a positive day for Valeant Pharmaceuticals International Inc. (VRX:CA) as its stock finished the day having gained 5.03% to hit a price of $19.00 a share. The company reached a market cap of 6.6 billion and has 347.33 …
Join Ken Calhoun each week for a new episode of Breakout Chart of the Week for stock swing traders and day traders. Today’s two swing trading charts: PLSE, …